

SUPPLEMENTARY TABLE

Supplementary table. Median (range) percentage change from baseline for IgA, IgG and IgM at week 12 (safety analysis). Data are based on absolute counts.

	Placebo	Epratumab				
	(n=38)	200 mg cd (100 mg EOW) (n=39)	800 mg cd (400 mg EOW) (n=38)	2400 mg cd (600 mg weekly) (n=35)	2400 mg cd (1200 mg EOW) (n=37)	3600 mg cd (1800 mg EOW) (n=38)
IgA	2.5 (-25-72)	6.0 (-82-55)	6.9 (-15-44)	12.8 (-10-97)	6.5 (-23-71)	11.4 (-40-145)
IgG	1.4 (-40-74)	4.3 (-38-48)	2.8 (-23-85)	14.3 (-35-70)	7.0 (-21-76)	-0.3 (-38-185)
IgM	-1.5 (-37-87)	-2.1 (-40-35)	-3.2 (-46-52)	-5.3 (-35-79)	-10.0 (-43-54)	-4.6 (-51-248)

EOW, every other week